Sevcenco S, et al. - In this retrospective study, the researchers evaluated the uptake behavior in the clinical setting of 64Copper Prostate-Specific Membrane Antigen (⁶⁴Cu PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) in prostate cancer. This research was conducted on twenty-three patients with intermediate, high risk and progressive disease at primary staging of prostate cancer. All subjects underwent ⁶⁴Cu-PSMA PET. In patients with recurrent or primary progressive prostate cancer, ⁶⁴Cu NODAGA-PSMA PET was a promising imaging tool in the detection of residual disease.